#TumorBoardTuesday 📊Who feels overwhelmed🌊by all the potential uses of ctDNA🧬testing in colon cancer🙋 📢Well then join us Tuesday, 10-14-25 at 8PM ET as @aparna1024 & @EmerikOsterlund🗣️the use of ctDNA in CRC RT and bring others into the discussion‼️

@GIMedOnc @TumorBoardTues @aparna1024 @IntegrityCE Clinical trials would certainly be an option. However, many of them require prior standard-of-care adjuvant therapy for eligibility.

Glow, strength and energy, Keto Collagen delivers more.*

@TumorBoardTues @aparna1024 @IntegrityCE @MPishvaian #TumorBoardTuesday @TumorBoardTues Thank you very much for the opportunity to host this session, I had a blast!😃

@HannahAlison20 @TumorBoardTues @aparna1024 @IntegrityCE @MPishvaian I am glad to hear that, thank you very much for participating and contributing!

@EmerikOsterlund @TumorBoardTues @aparna1024 @IntegrityCE @MPishvaian Thank you so much! This was very informative and easy for the APP to follow. I learned a lot. #TumorBoardTuesday

Are you looking for the best IT Service provider in the country? Get in touch with our expert team to learn how we can help your business!

@MPishvaian @TumorBoardTues @aparna1024 @IntegrityCE Really challenging indeed, to say the least 🤔

@TumorBoardTues @aparna1024 @IntegrityCE #TumorBoardTuesday @TumorBoardTues Thank you very much for the opportunity to present! @aparna1024 for great co-operation of preparing the and conducting the session! @MPishvaian for your great comments and questions!

@EmerikOsterlund @TumorBoardTues @aparna1024 @IntegrityCE #TumorBoardTuesday A conversation I have regularly with my patients is: - If the ctDNA turns➕, the most I would do (in the absence of a trial) is to scan you more frequently - So in that context, I alternate...and if the ctDNA turns➕, then I move up the scans

@yeung_cynthia @TumorBoardTues @aparna1024 @IntegrityCE Thank you very much! I am a firm believer in tumor informed assays in the MRD setting, as long as we have tumor material for designing them.

@TumorBoardTues @aparna1024 @IntegrityCE #PostTest Q2️⃣ #TumorBoardTuesday 👉🏽 Free CME 🔗 https://t.co/2Jdml74CPZ 🧐70M, frail + comorbidities, s/p upfront surgery for sigmoid mass. Final pathology: pT3N0 (stage IIA). 2 months post-op: ctDNA-negative. What’s next?

@TumorBoardTues @aparna1024 @IntegrityCE #PostTest Q1️⃣ #TumorBoardTuesday 👉🏽#CME Eval 🔗 https://t.co/pWxDXtEGHz 👉🏽ALL CME🔗 https://t.co/2Jdml74CPZ 🧐ctDNA monitoring after CRC resection:

@EmerikOsterlund @TumorBoardTues @aparna1024 @IntegrityCE #TumorBoardTuesday This is great data - but it is really hard to make use of it with the patient in front of you....because you don't know that the clearance is "transient" until it is no longer ctDNA negative 😕

Future Of DePIN Series Kickoff!

@EmerikOsterlund @TumorBoardTues @aparna1024 @IntegrityCE Thank you for a very informative #TumorBoardTuesday, @EmerikOsterlund! What are your thoughts on tumor informed vs tumor agnostic assays for the MRD space in CRC?

@MPishvaian @EmerikOsterlund @TumorBoardTues @IntegrityCE This was confusing at first as was different than original dfs data for t4no. Updated assay run subsequently.

@EmerikOsterlund @TumorBoardTues @aparna1024 @IntegrityCE #TumorBoardTuesday Nahhhh - not in this scenario

@TumorBoardTues @aparna1024 @IntegrityCE 23/23 #TumorBoardTuesday 🔑Takeaways 2/2 ✅Stage 2 CRC: ctDNA⛔️; ❓consider chemo de-escalation/avoidance 🔁Serial testing matters; On-treatment ctDNA “clearance” can be transient 🧪Pair ctDNA with clinical assessment and 🩻; assay & timing matters

“In an age of killer submarines and cyber warfare, one might reasonably ask what old warriors from long-gone conflicts have to teach us about war today. Quite a lot, it turns out.” Read “Model officers” by Henrik Bering from the September issue of The New Criterion:

@VivekSubbiah @EmerikOsterlund @TumorBoardTues @aparna1024 @IntegrityCE @Annals_Oncology #TumorBoardTuesday Excellent thought - and so good to see you weighing in tonight @VivekSubbiah 😃😃😃

@EmerikOsterlund @TumorBoardTues @aparna1024 @IntegrityCE #TumorBoardTuesday It goes so much against the grain of the last 10-20 years......but I still think (and the data supports) that you have to give adjuvant chemo in this case

@TumorBoardTues @aparna1024 @IntegrityCE 22/23 #TumorBoardTuesday 🔑Takeaways 1/2 🧬ctDNA useful for MRDdetection after surgery ⚠️ ctDNA➕→ very high recurrence risk; ❓consider adjuvant/intensified chemo

@EmerikOsterlund @TumorBoardTues @aparna1024 @IntegrityCE #TumorBoardTuesday YES!! Highly anticipated😃

@TumorBoardTues @aparna1024 @IntegrityCE 21/23 #TumorBoardTuesday 🧠🍽️ Food for thought: considering that the testing costs $3–4K per ctDNA draw 💸 📊 Poll: For a self-pay patient, would you recommend ctDNA monitoring?